DexCom sees FY24 revenue $4.15B-$4.35B, consensus $4.32B

Sees FY24 gross profit margin 63%-64%. Sees FY24 operating margin 20%. The company said, “For 2024, Dexcom currently anticipates total revenue of approximately $4.15 billion to $4.35 billion, representing expected organic growth1 of approximately 16% to 21% over 2023. This outlook considers sensor volume growth driven by increasing CGM access and awareness for people with diabetes, the introduction of Dexcom’s product for people who do not use insulin, further international expansion, and overall market dynamics.”